Teva Pharmaceutical Industries price to free cash flow TEVA
Market value divided by free cash flow over the last twelve months, since 2018.
- Today, Nov 3, 2026
- 36.9×
- 8-year median
- 21.9×
- Against its 8-year history
- 84th
- percentile: 0 is its lowest day, 100 its highest
- 8-year range
- 4.4× to 119×
- Peer median
- 30.2×
Teva Pharmaceutical Industries' price to free cash flow is 36.9× as of Nov 3, 2026.
That is above its 8-year median of 21.9×, higher than on 84% of days in the last 8 years.
Over that time it ranged from 4.4× in Dec 2018 to 119× in Nov 2021.
The median for 10 healthcare stocks of a similar size is 30.2×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 35.2× | 28.6× | 67.6× |
| 2025 | 63.3× | 14.7× | 63.3× |
| 2024 | 18.9× | 13.6× | 31.5× |
| 2023 | 19.2× | 7.8× | 24.3× |
| 2022 | 19.7× | 13.3× | 115× |
| 2021 | 100× | 13.1× | 119× |
| 2020 | 11.7× | 10.7× | 64.6× |
| 2019 | 109× | 5.0× | 109× |
| 2018 | 4.5× | 4.4× | 6.8× |
Against its peers
Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| TEVATeva Pharmaceutical Industries | 36.9× |
| AAgilent Technologies | 39.1× |
| HUMHumana | 25.4× |
| MDLNMedline | n/m |
| WATWaters | 117× |
| IQVIQVIA | 19.4× |
| IDXXIDEXX Laboratories | 41.5× |
| EWEdwards Lifesciences | 38.1× |
| BDXBecton, Dickinson and | 19.8× |
| ONCBeOne Medicines | 30.2× |
| RPRXRoyalty Pharma | 14.1× |
| Peer median | 30.2× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Teva Pharmaceutical Industries
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.